Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing innovative therapeutic products for high unmet patient needs. Its primary function is to develop and launch treatments like ZELSUVMI™, a novel therapeutic product for Molluscum contagiosum infections. Notably, Pelthos Therapeutics leverages its proprietary nitric oxide-based technology platform to address significant medical challenges. The company operates in the pharmaceutical sector, specifically targeting dermatological conditions. With a strong pipeline of potential product candidates, Pelthos aims to deliver impactful treatments to patients across various demographics. Its market significance lies in addressing unmet medical needs through pioneering therapeutic innovations.